20 batches of counterfeit and inferior drugs are discontinued and 10 companies with multiple varieties are recalled

Original title: Recall of 20 lots of counterfeit and substandard medicines

The official website of the State Food and Drug Administration recently published the “Regarding 20 batches of drugs that do not meet the requirementsnotice“According to the 7Inspection agencyInspection, labeled as Tonghua Boxiang Pharmaceutical of Jilin ProvinceSharelimitedthe companyWaiting for 10 pharmaceutical productionbusinessThe 20 batches of drugs produced did not comply with the regulations. The reporter noted that the varieties exhibited this time include both proprietary Chinese medicines and Western medicines, the patented Chinese medicines became the recall.Main force“Military”, the main element of non-compliance involved is that the traits do not meet the requirements.

　　20 drug batches from 10 companies fail to comply with regulations

The Food and Drug Administration stated that drug oversightadministrationThe department has asked the relevant companies and units to take a suspensionSalesUse, recover, etc.riskControl measures, investigate the reasons for non-compliance with regulations and correct them effectively. The pharmaceutical regulatory department has organized the illegal production and sale of counterfeit and inferior drugs by companies and related unitsbehaviorInvestigate the case and publish the results of the investigation as necessary.

It is reportedly labeled as Jilin Province Tonghua Boxiang Pharmaceutical Co., Ltd.Limited liability company, Jilin Shuangshi Pharmaceutical Co., Ltd. City, Jilin Tiantai Pharmaceutical Co., Ltd.Company Limited by SharesThe 12 batches of Dendrobium Yeguang Pills produced did not meet the requirements; labeled as HainanPuli PharmaceuticalThe first batch of sustained-release clarithromycin tablets produced by the stock-limited company did not meet the requirements, and the non-compliant items were lost to drying; labeled as ShanxiQianyuan PharmaceuticalA batch of azlocillin sodium for injection produced by Group Co., Ltd. does not comply with regulations. The element that does not comply with the regulations is the clarity of the solution; the label is Hebei Guojin Pharmaceutical Co., Ltd.responsibilityThe two batches of honeysuckle composite granules produced by the company and Guangzhou Huacheng Pharmaceutical Co., Ltd. did not comply with the regulations, and the non-compliant items were the difference in the filling quantity; labeled Anhui Zehua National Medicine Decoction Pieces Co., Ltd. produced 1 batch of Rhodiola and 1 batch Chuanwu subsystem does not meet the requirements, and the items that do not meet the requirements are all traits; the first batch of Qianhu produced by Anguo Tongkang Pharmaceutical Co., Ltd. does not meet the requirements, and the items that do not meet the requirements are traits and identification; labeled as Hunan province A batch of Gentiana produced by Naturaltang Chinese Medicine Decoction Pieces Co., Ltd. did not meet the requirements, and the items that did not meet the requirements were traits.

　　Patented drugs and Chinese decoction pieces become the “main force” withdrawn

What is a trait that does not meet the requirements? Introduction from the Food and Drug Administration: Appearance, odor, taste, solubility, and physical constants are included in the traits item, which to some extent reflects the characteristics of the drug.qualitycharacteristic. “TCM decoction pieces do not meet the requirements, which may lead to deviations inArtDefects, improper storage, etc. “The experts said so.

The reporter combed his hair and discovered that the exposedproductIncluding 12 lots of Dendrobium glow pills, 2 lots of compound honeysuckle granules, 1 lot of Rhodiola and 1 lot of Chuan, 1 lot of Qianhu and 1 lot of Gentiana, which means there are 18 lots of products in 20 lots. The batch is proprietary Chinese medicine and decoction pieces. “Chinese patented medicines and decoction pieces are still the ‘severe disaster areas’ with poor quality. The situation has improved a lot in recent years with rectification, but poor products are still exposed from time to time,” said an industry observer.

(Source: Guangzhou Daily)

(Responsible editor: DF524)